Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budoprutug (TNT119) in adults with immune thrombocytopenia
2024-519745-30-01Phase 2Authorised
- Sponsor
- Climb Bio
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of budoprutug in immune thrombocytopenia (ITP), sponsored by Climb Bio. Primary endpoint: Safety and tolerability of budoprutug. Planned start Dec 2025; status: authorised.
02
Drugs
budoprutug
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2024-519745-30-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519745-30-01.